MYLK3 and type 1 diabetes mellitus: In summary, this study demonstrated that a 5-HT4R agonist alleviated T1D-induced disruption of the TJ barrier, decreased the expressions of TJ proteins, including occludin, claudin-1, and ZO-1, and increased the expressions of MLCK, ROCK1, and p-MLC.